AstraZeneca India is preparing to sell its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations.
The move aligns with the parent company’s broader strategy to optimize resources through corporate land monetization.
The Potential Deal
The proposed sale could generate more than ₹32 billion. AstraZeneca India has engaged global property consultants to identify potential buyers, with the land valued at over ₹500 million per acre. Previous efforts to sell the facility faced challenges due to its high valuation, making it difficult to secure a deal.
Looking for a Buyer to Maintain Operations
AstraZeneca plans to transfer the facility as a fully operational unit.
The company is actively seeking a buyer who can also function as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to regulatory approvals.
Facility’s Role in AstraZeneca’s Global Network
The Bengaluru facility plays a crucial role in AstraZeneca’s global network, serving as one of nine sites dedicated to clinical trial design and execution.
As reported by constructionworld.in, the planned sale reflects the company’s strategic shift to streamline global operations while ensuring continued pharmaceutical production through external partnerships.
